AU2016365751B2 - Use of C-type natriuretic peptide variants to treat osteoarthritis - Google Patents

Use of C-type natriuretic peptide variants to treat osteoarthritis Download PDF

Info

Publication number
AU2016365751B2
AU2016365751B2 AU2016365751A AU2016365751A AU2016365751B2 AU 2016365751 B2 AU2016365751 B2 AU 2016365751B2 AU 2016365751 A AU2016365751 A AU 2016365751A AU 2016365751 A AU2016365751 A AU 2016365751A AU 2016365751 B2 AU2016365751 B2 AU 2016365751B2
Authority
AU
Australia
Prior art keywords
cnp
gly
subject
seq
osteoarthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016365751A
Other languages
English (en)
Other versions
AU2016365751A1 (en
Inventor
Charles A. O'neill
Todd M. Oppeneer
Jason K. Pinkstaff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of AU2016365751A1 publication Critical patent/AU2016365751A1/en
Application granted granted Critical
Publication of AU2016365751B2 publication Critical patent/AU2016365751B2/en
Priority to AU2024201852A priority Critical patent/AU2024201852A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016365751A 2015-12-08 2016-12-08 Use of C-type natriuretic peptide variants to treat osteoarthritis Active AU2016365751B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201852A AU2024201852A1 (en) 2015-12-08 2024-03-21 Use of C-type natriuretic peptide variants to treat osteoarthritis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
US62/264,682 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201852A Division AU2024201852A1 (en) 2015-12-08 2024-03-21 Use of C-type natriuretic peptide variants to treat osteoarthritis

Publications (2)

Publication Number Publication Date
AU2016365751A1 AU2016365751A1 (en) 2018-06-21
AU2016365751B2 true AU2016365751B2 (en) 2023-12-21

Family

ID=59013378

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016365751A Active AU2016365751B2 (en) 2015-12-08 2016-12-08 Use of C-type natriuretic peptide variants to treat osteoarthritis
AU2024201852A Pending AU2024201852A1 (en) 2015-12-08 2024-03-21 Use of C-type natriuretic peptide variants to treat osteoarthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201852A Pending AU2024201852A1 (en) 2015-12-08 2024-03-21 Use of C-type natriuretic peptide variants to treat osteoarthritis

Country Status (17)

Country Link
US (2) US11202819B2 (https=)
EP (2) EP4019038A3 (https=)
JP (1) JP7104625B2 (https=)
KR (1) KR102941538B1 (https=)
CN (1) CN108697766A (https=)
AU (2) AU2016365751B2 (https=)
CA (1) CA3007315A1 (https=)
DK (1) DK3386531T3 (https=)
ES (1) ES2901769T3 (https=)
HR (1) HRP20211908T1 (https=)
HU (1) HUE057083T2 (https=)
IL (1) IL259690B2 (https=)
MX (1) MX2018006986A (https=)
PL (1) PL3386531T3 (https=)
PT (1) PT3386531T (https=)
RU (1) RU2759679C2 (https=)
WO (1) WO2017100400A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
DK3400019T3 (da) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
BR112020021966A2 (pt) * 2018-04-27 2021-01-26 Remy Biosciences, Inc. dispositivos médicos, veículos de liberação e fabricação dos mesmos
MX2021008708A (es) * 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
US20240238428A1 (en) * 2021-05-11 2024-07-18 Texas Tech University System Targeted selenium conjugates as countermeasures for viral and cellular pathogens
EP4444341A1 (en) * 2021-12-07 2024-10-16 BioMarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070017366A (ko) * 2004-03-31 2007-02-09 추가이 세이야쿠 가부시키가이샤 관절염증 치료제 또는 예방제
US20100297021A1 (en) * 2009-05-20 2010-11-25 Biomarin Pharmaceutical Inc. Variants of C-Type Natriuretic Peptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
WO2005094890A1 (ja) * 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070017366A (ko) * 2004-03-31 2007-02-09 추가이 세이야쿠 가부시키가이샤 관절염증 치료제 또는 예방제
EP1759710A1 (en) * 2004-03-31 2007-03-07 Kazuwa Nakao Remedy or preventive for arthritis
US20100297021A1 (en) * 2009-05-20 2010-11-25 Biomarin Pharmaceutical Inc. Variants of C-Type Natriuretic Peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICK J. PEAKE ET AL: "Controlled Release of C-Type Natriuretic Peptide by Microencapsulation Dampens Proinflammatory Effects Induced by IL-1[beta] in Cartilage Explants", BIOMACROMOLECULES, vol.16, no.2, 9 Feb 2015 (2015-02-09), p524-531 *

Also Published As

Publication number Publication date
CN108697766A (zh) 2018-10-23
CA3007315A1 (en) 2017-06-15
US20190247467A1 (en) 2019-08-15
EP3386531A2 (en) 2018-10-17
EP3386531B1 (en) 2021-10-13
RU2018124600A (ru) 2020-01-13
ES2901769T3 (es) 2022-03-23
KR102941538B1 (ko) 2026-03-19
US12214015B2 (en) 2025-02-04
HUE057083T2 (hu) 2022-04-28
RU2759679C2 (ru) 2021-11-16
WO2017100400A3 (en) 2017-10-26
IL259690B2 (en) 2023-02-01
HRP20211908T1 (hr) 2022-03-04
DK3386531T3 (da) 2022-01-03
JP2019505486A (ja) 2019-02-28
EP4019038A3 (en) 2022-09-28
WO2017100400A2 (en) 2017-06-15
KR20180088459A (ko) 2018-08-03
EP4019038A2 (en) 2022-06-29
IL259690A (en) 2018-07-31
PT3386531T (pt) 2021-12-29
AU2016365751A1 (en) 2018-06-21
PL3386531T3 (pl) 2022-02-28
US11202819B2 (en) 2021-12-21
IL259690B (en) 2022-10-01
AU2024201852A1 (en) 2024-04-11
JP7104625B2 (ja) 2022-07-21
US20220160836A1 (en) 2022-05-26
MX2018006986A (es) 2018-09-05
RU2018124600A3 (https=) 2020-01-13
RU2021132347A (ru) 2022-03-24

Similar Documents

Publication Publication Date Title
AU2016365751B2 (en) Use of C-type natriuretic peptide variants to treat osteoarthritis
USRE48267E1 (en) Variants of C-type natriuretic peptide
AU2008326327A1 (en) Variants of C-type natriuretic peptide
HK40074902A (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
RU2850341C2 (ru) Применение вариантов натрийуретического пептида типа c для лечения остеоартрита
HK1262398B (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
HK40130436A (en) Variants of c-type natriuretic peptide
HK40124042A (en) Variants of c-type natriuretic peptide
HK1239519B (en) Variants of c-type natriuretic peptide
HK1239519A1 (en) Variants of c-type natriuretic peptide
HK1168279B (en) Variants of c-type natriuretic peptide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)